Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Enhanced fracture repair by leukotriene antagonism is characterized by increased chondrocyte proliferation and early bone formation: a novel role of the cysteinyl LT-1 receptor.

Wixted JJ, Fanning PJ, Gaur T, O'Connell SL, Silva J, Mason-Savas A, Ayers DC, Stein GS, Lian JB.

J Cell Physiol. 2009 Oct;221(1):31-9. doi: 10.1002/jcp.21809.

2.

Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Shimbori C, Shiota N, Okunishi H.

Eur J Pharmacol. 2011 Jan 10;650(1):424-30. doi: 10.1016/j.ejphar.2010.09.084. Epub 2010 Oct 27.

PMID:
21034736
3.

[The role of leukotrienes in inflammation and leukotriene inhibitors].

Kupczyk M, Kuna P.

Pol Merkur Lekarski. 1999 Sep;7(39):85-93. Review. Polish.

PMID:
10598480
4.

Effects of zileuton and montelukast in mouse experimental spinal cord injury.

Genovese T, Rossi A, Mazzon E, Di Paola R, Muià C, Caminiti R, Bramanti P, Sautebin L, Cuzzocrea S.

Br J Pharmacol. 2008 Feb;153(3):568-82. Epub 2007 Dec 3.

5.

The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.

Said MM, Bosland MC.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):197-205. doi: 10.1007/s00210-016-1325-4. Epub 2016 Dec 1.

PMID:
27909742
6.

Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.

Holma R, Salmenperä P, Riutta A, Virtanen I, Korpela R, Vapaatalo H.

Eur J Pharmacol. 2001 Oct 19;429(1-3):309-18.

PMID:
11698051
7.

Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation.

Nieves D, Moreno JJ.

Biochem Pharmacol. 2006 Oct 16;72(8):1022-30. Epub 2006 Aug 28.

PMID:
16934759
8.

The effects of leukotriene receptor antagonist montelukast on histological, radiological and densitometric parameters of fracture healing.

Cakıcı H, Hapa O, Gideroğlu K, Ozturan K, Güven M, Yüksel HY, Yılmaz F.

Eklem Hastalik Cerrahisi. 2011;22(1):43-7.

9.

Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis.

Di Capite J, Nelson C, Bates G, Parekh AB.

J Allergy Clin Immunol. 2009 Nov;124(5):1014-21.e1-3. doi: 10.1016/j.jaci.2009.08.030.

PMID:
19895990
10.

Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures.

Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, Wigner NA, Toben D, Jacobsen KA, Al-Sebaei MO, Song M, Trackman PC, Morgan EF, Gerstenfeld LC, Barnes GL.

J Bone Miner Res. 2007 Dec;22(12):1903-12.

11.

Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing.

Cottrell JA, O'Connor JP.

J Bone Joint Surg Am. 2009 Nov;91(11):2653-65. doi: 10.2106/JBJS.H.01844.

PMID:
19884440
12.

Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes.

Di Capite J, Shirley A, Nelson C, Bates G, Parekh AB.

FASEB J. 2009 Mar;23(3):894-905. doi: 10.1096/fj.08-118935. Epub 2008 Oct 31.

PMID:
18978154
13.

Blockade of avidity and focal clustering of beta 2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion.

Meliton AY, Munoz NM, Leff AR.

J Allergy Clin Immunol. 2007 Dec;120(6):1316-23. Epub 2007 Sep 29.

PMID:
17904626
14.

Effects of cysteinyl-leukotriene receptors' antagonism by montelukast on lung mechanics and olfactory system histology in healthy mice.

Rubini A, Bondì M, Mucignat-Caretta C.

J Enzyme Inhib Med Chem. 2012 Aug;27(4):521-7. doi: 10.3109/14756366.2011.599031. Epub 2011 Aug 10.

PMID:
21827367
15.

Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.

Ikeda G, Miyahara N, Koga H, Fuchimoto Y, Waseda K, Kurimoto E, Taniguchi A, Tanimoto Y, Kataoka M, Tanimoto M, Kanehiro A.

Am J Respir Cell Mol Biol. 2014 Jan;50(1):18-29. doi: 10.1165/rcmb.2012-0418OC.

PMID:
23937413
16.

Leukotriene synthesis inhibitors versus antagonists: the pros and cons.

Steinke JW, Culp JA.

Curr Allergy Asthma Rep. 2007 May;7(2):126-33. Review.

PMID:
17437683
17.
18.

Transforming growth factor β1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1.

Huang XQ, Zhang XY, Wang XR, Yu SY, Fang SH, Lu YB, Zhang WP, Wei EQ.

J Neuroinflammation. 2012 Jun 26;9:145. doi: 10.1186/1742-2094-9-145.

19.

Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.

Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, Nakatani T, Yoshimura R.

Oncol Rep. 2007 Jul;18(1):99-104.

PMID:
17549353
20.

Montelukast, a selective cysteinyl leukotriene receptor 1 antagonist, reduces cerulein-induced pancreatic injury in rats.

Ozkan E, Akyüz C, Sehirli AO, Topaloğlu U, Ercan F, Sener G.

Pancreas. 2010 Oct;39(7):1041-6. doi: 10.1097/MPA.0b013e3181db2dfd.

PMID:
20467345

Supplemental Content

Support Center